Hansa Biopharma to host Q2 2024 interim results conference call

Rhea-AI Summary

Hansa Biopharma (NASDAQ Stockholm: HNSA) announced it will publish its interim report for January-June 2024 on July 18, 2024. The company will host a quarterly conference call on the same day at 14:00 CEST/8:00 AM EST, featuring presentations from key executives including CEO Søren Tulstrup and CFO Evan Ballantyne. The call will provide a comprehensive review of the interim results along with a business and pipeline update. The event will be conducted in English, and presentation slides will be available on the Hansa Biopharma website.

Interested participants can join the call using the provided dial-in details for Sweden, the UK, and the US, or access the live webcast through the company's event webpage.

Positive

• The upcoming conference call will provide detailed insights into Hansa Biopharma's interim results and business pipeline updates, which may offer positive guidance for investors.

Negative

• The release does not include any preliminary figures or performance estimates, leaving investors uncertain about the company's financial health until the call.

LUND, Sweden, July 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren Tulstrup, President and CEO, Matthew Shaulis, CCO and US President, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO. The call will include a review of the interim results and a business and pipeline update. It will be held in English.

Slides used in the presentation will be made available on the company website at the following link: Financial reports.

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46-8-1241-0952

United Kingdom: +44-203-7696819

United States: +1 646-787-0157

Participant access code: 765135

The webcast will be available on https://hansabiopharma.eventcdn.net/events/half-year-january-june-2024

Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com

Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-host-q2-2024-interim-results-conference-call,c4006606

The following files are available for download:

https://mb.cision.com/Main/1219/4006606/2885437.pdf

240703 - HNSA - Q2 2024 Conf call_ENG invite

 

View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-to-host-q2-2024-interim-results-conference-call-302188678.html

SOURCE Hansa Biopharma AB

FAQ

When will Hansa Biopharma publish its interim report for January-June 2024?

Hansa Biopharma will publish its interim report for January-June 2024 on July 18, 2024.

What time is Hansa Biopharma's Q2 2024 interim results conference call?

The conference call is scheduled for July 18, 2024, at 14:00 CEST/8:00 AM EST.

Who will be presenting at Hansa Biopharma's Q2 2024 interim results conference call?

The call will feature presentations from Søren Tulstrup (CEO), Matthew Shaulis (CCO and US President), Evan Ballantyne (CFO), and Hitto Kaufmann (CR&DO).

How can investors join Hansa Biopharma's Q2 2024 interim results conference call?

Investors can join the call by dialing the provided numbers for Sweden, the UK, and the US, or by accessing the live webcast on Hansa Biopharma's event page.

What will be discussed during Hansa Biopharma's Q2 2024 interim results conference call?

The call will include a review of the interim results, and updates on the company's business and pipeline.